VIVAC
Viscogel - A chitosan based adjuvant for prophylactic and therapeutic vaccination
| Coordinatore | Viscogel AB
Organization address
address: Gunnar Asplunds Alle 32 contact info |
| Nazionalità Coordinatore | Sweden [SE] |
| Totale costo | 1˙496˙400 € |
| EC contributo | 1˙155˙362 € |
| Programma | FP7-SME
Specific Programme "Capacities": Research for the benefit of SMEs |
| Code Call | FP7-SME-2010-1 |
| Funding Scheme | BSG-SME |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-09-01 - 2012-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
Viscogel AB
Organization address
address: Gunnar Asplunds Alle 32 contact info |
SE (Solna) | coordinator | 735˙596.50 |
| 2 |
Inmunotek SL
Organization address
address: Calle Velazquez 124 contact info |
ES (Madrid) | participant | 293˙343.75 |
| 3 |
Lytix Biopharma AS
Organization address
address: Sykehusveien 23 contact info |
NO (Tromso) | participant | 126˙422.25 |
| 4 |
HACETTEPE UNIVERSITESI
Organization address
address: HACETTEPE UNIVERSITESI BEYTEPE KAMPUSU REKTORLUK BINASI contact info |
TR (CANKAYA ANKARA) | participant | 0.00 |
| 5 |
Huntingdon Life Sciences Ltd
Organization address
address: Woolley Road contact info |
UK ("Alconbury, Huntingdon") | participant | 0.00 |
| 6 |
KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
SE (STOCKHOLM) | participant | 0.00 |
| 7 |
NORGES TEKNISK-NATURVITENSKAPELIGEUNIVERSITET NTNU
Organization address
address: HOGSKOLERINGEN 1 contact info |
NO (TRONDHEIM) | participant | 0.00 |
| 8 |
PHARMA CONSULTING GROUP IN UPPSALA AB
Organization address
address: KUNGSANGSVAGEN 19 contact info |
SE (UPPSALA) | participant | 0.00 |
| 9 |
Stallergenes SA
Organization address
address: Rue Alexis De Tocqueville 6 contact info |
FR (ANTONY) | participant | 0.00 |
| 10 |
STOCKHOLMS LAENS LANDSTING
Organization address
address: Hantverkargatan 45 contact info |
SE (STOCKHOLM) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The overall aim of the ViVac project is to develop and to show safety and efficacy for a new innovative carbohydrate (chitosan) based adjuvant -Viscogel –to be used both in prophylactic and therapeutic vaccination. Three SME participants will contribute with their specific technologies: the unique Viscogel technology, a specific type of cationic peptides with cell-penetrating capacity (LTX) and a technology platform for production of recombinant allergens (Bet v 1). Viscogel has excellent adjuvant properties: strongly immunostimulatory, stable, easy to manufacture, pronounced depot effect and possibility to obtain products of GMP quality. In addition Viscogel is mucoadhesive and in combination with LTX cell penetrating, making it suitable for mucosal administration. The target applications to be demonstrated in the ViVac project are i) prophylactic vaccination against common infectious diseases, and ii) therapeutic allergy vaccination. Both application areas represent billion € markets. Five RTD consortium partners with specific key competences will perform research to support further technical development and new IP opportunities for the participating SME partners. The research objectives are i) to provide pre-clinical and clinical proof-of-concept for prophylactic vaccination with a model vaccine against Hib (Haemophilus influenzae type b). Data supporting that Viscogel induces improved immune responses at lower vaccine doses will likely be applicable to most prophylactic vaccines. ii) to provide pre-clinical proof-of-concept for therapeutic vaccination, demonstrated for allergy vaccination. In particular Viscogel-Bet v 1 formulations for administration over the sublingual mucosa will be developed and thus fulfil an unmet medical need for safe, efficient and convenient allergy vaccination. A successful outcome of the ViVac project will significantly improve the competitive situation for the SME partners and create new commercialisation opportunities.'
Introduzione (Teaser)
A European consortium tested the efficacy of a novel carbohydrate-based adjuvant for prophylactic and therapeutic vaccination. Apart from increased efficacy, exploitation of this simple and inexpensive technology enables reduced cost of vaccine production, making them more affordable for developing countries.